HK1202444A1 - 結合蛋白 - Google Patents
結合蛋白Info
- Publication number
- HK1202444A1 HK1202444A1 HK15103143.3A HK15103143A HK1202444A1 HK 1202444 A1 HK1202444 A1 HK 1202444A1 HK 15103143 A HK15103143 A HK 15103143A HK 1202444 A1 HK1202444 A1 HK 1202444A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- binding proteins
- proteins
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161562245P | 2011-11-21 | 2011-11-21 | |
US201161562728P | 2011-11-22 | 2011-11-22 | |
PCT/US2012/065872 WO2013078135A2 (en) | 2011-11-21 | 2012-11-19 | Il-1 binding proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1202444A1 true HK1202444A1 (zh) | 2015-10-02 |
Family
ID=48470408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15103143.3A HK1202444A1 (zh) | 2011-11-21 | 2015-03-27 | 結合蛋白 |
Country Status (24)
Country | Link |
---|---|
US (1) | US20140348838A1 (zh) |
EP (1) | EP2782601A4 (zh) |
JP (1) | JP2015500206A (zh) |
KR (1) | KR20140097430A (zh) |
CN (1) | CN104203278A (zh) |
AU (1) | AU2012340878A1 (zh) |
BR (1) | BR112014012121A2 (zh) |
CA (1) | CA2856582A1 (zh) |
CL (1) | CL2014001349A1 (zh) |
CO (1) | CO6990666A2 (zh) |
CR (1) | CR20140279A (zh) |
DO (1) | DOP2014000111A (zh) |
EC (1) | ECSP14005992A (zh) |
GT (1) | GT201400099A (zh) |
HK (1) | HK1202444A1 (zh) |
IL (1) | IL232674A0 (zh) |
IN (1) | IN2014CN04582A (zh) |
MX (1) | MX2014006160A (zh) |
PE (1) | PE20141941A1 (zh) |
PH (1) | PH12014501138A1 (zh) |
RU (1) | RU2014125220A (zh) |
SG (1) | SG11201402533YA (zh) |
WO (1) | WO2013078135A2 (zh) |
ZA (1) | ZA201404481B (zh) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI465250B (zh) | 2009-08-29 | 2014-12-21 | Abbvie Inc | 治療用之dll4結合蛋白質 |
EP2542582A4 (en) | 2010-03-02 | 2013-12-04 | Abbvie Inc | THERAPEUTIC PROTEINS LINKING TO DLL4 |
CA2807014A1 (en) | 2010-08-03 | 2012-02-09 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
RU2015134562A (ru) * | 2011-02-08 | 2018-12-24 | Эббви Инк. | Лечение остеоартрита и боли |
AU2013337775B2 (en) | 2012-11-01 | 2017-03-30 | Abbvie Inc. | Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof |
WO2015084883A2 (en) | 2013-12-02 | 2015-06-11 | Abbvie, Inc. | Compositions and methods for treating osteoarthritis |
WO2015138337A1 (en) | 2014-03-09 | 2015-09-17 | Abbvie, Inc. | Compositions and methods for treating rheumatoid arthritis |
US20160002326A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Compositions and methods for treating rheumatoid arthritis |
US20160000936A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
US10399874B2 (en) | 2014-12-11 | 2019-09-03 | Lg Electronics Inc. | Drinking water supply device and method of controlling a drinking water supply device |
US10031533B2 (en) | 2014-12-11 | 2018-07-24 | Lg Electronics Inc. | Drinking water supply device |
US10077544B2 (en) | 2014-12-11 | 2018-09-18 | Lg Electronics Inc. | Drinking water supply device |
KR101629334B1 (ko) * | 2015-01-27 | 2016-06-10 | 엘지전자 주식회사 | 음용수 공급장치 및 이의 제어방법 |
US20160244520A1 (en) | 2015-01-24 | 2016-08-25 | Abbvie Inc. | Compositions and methods for treating psoriatic arthritis |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
KR20180134880A (ko) * | 2016-03-09 | 2018-12-19 | 슈 생-쥐스땡 | 주산기 이환율 및/또는 사망률을 감소시키는 방법 |
CN106344935B (zh) * | 2016-10-11 | 2020-01-07 | 武汉大学 | Toll样蛋白相互作用蛋白在治疗血管损伤后再狭窄中的功能和应用 |
CN110680905A (zh) * | 2019-10-24 | 2020-01-14 | 内蒙古医科大学第二附属医院 | Tslp在制备治疗腰椎间盘突出药物中的应用 |
CN114113624A (zh) * | 2020-08-28 | 2022-03-01 | 香港城市大学深圳研究院 | 利用免疫球蛋白关联蛋白质组开发疾病标志物的方法及装置 |
CN116930385B (zh) * | 2023-08-08 | 2024-02-20 | 北京爱思益普生物科技股份有限公司 | 一种高盐浓度制剂中化合物浓度的测定方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080074231A (ko) * | 2000-06-29 | 2008-08-12 | 아보트 러보러터리즈 | 이중 특이성 항체 및 이의 제조 및 사용 방법 |
EP2114443A4 (en) * | 2006-12-29 | 2011-08-10 | Abbott Lab | IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY |
EP2571532B1 (en) * | 2010-05-14 | 2017-05-03 | Abbvie Inc. | Il-1 binding proteins |
-
2012
- 2012-11-19 AU AU2012340878A patent/AU2012340878A1/en not_active Abandoned
- 2012-11-19 CA CA2856582A patent/CA2856582A1/en not_active Abandoned
- 2012-11-19 BR BR112014012121A patent/BR112014012121A2/pt not_active IP Right Cessation
- 2012-11-19 CN CN201280067294.9A patent/CN104203278A/zh active Pending
- 2012-11-19 US US14/359,808 patent/US20140348838A1/en not_active Abandoned
- 2012-11-19 RU RU2014125220/15A patent/RU2014125220A/ru not_active Application Discontinuation
- 2012-11-19 EP EP12851661.4A patent/EP2782601A4/en not_active Withdrawn
- 2012-11-19 WO PCT/US2012/065872 patent/WO2013078135A2/en active Application Filing
- 2012-11-19 JP JP2014542551A patent/JP2015500206A/ja active Pending
- 2012-11-19 SG SG11201402533YA patent/SG11201402533YA/en unknown
- 2012-11-19 PE PE2014000722A patent/PE20141941A1/es not_active Application Discontinuation
- 2012-11-19 KR KR1020147017117A patent/KR20140097430A/ko not_active Application Discontinuation
- 2012-11-19 MX MX2014006160A patent/MX2014006160A/es unknown
-
2014
- 2014-05-18 IL IL232674A patent/IL232674A0/en unknown
- 2014-05-21 GT GT201400099A patent/GT201400099A/es unknown
- 2014-05-21 PH PH12014501138A patent/PH12014501138A1/en unknown
- 2014-05-21 DO DO2014000111A patent/DOP2014000111A/es unknown
- 2014-05-22 CL CL2014001349A patent/CL2014001349A1/es unknown
- 2014-06-13 CR CR20140279A patent/CR20140279A/es unknown
- 2014-06-16 CO CO14130059A patent/CO6990666A2/es unknown
- 2014-06-18 IN IN4582CHN2014 patent/IN2014CN04582A/en unknown
- 2014-06-18 ZA ZA2014/04481A patent/ZA201404481B/en unknown
- 2014-06-20 EC ECIEPI20145992A patent/ECSP14005992A/es unknown
-
2015
- 2015-03-27 HK HK15103143.3A patent/HK1202444A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
PE20141941A1 (es) | 2014-12-28 |
US20140348838A1 (en) | 2014-11-27 |
ZA201404481B (en) | 2016-01-27 |
CN104203278A (zh) | 2014-12-10 |
CL2014001349A1 (es) | 2014-10-10 |
ECSP14005992A (es) | 2015-06-30 |
DOP2014000111A (es) | 2014-07-15 |
PH12014501138A1 (en) | 2014-08-04 |
CA2856582A1 (en) | 2013-05-30 |
WO2013078135A2 (en) | 2013-05-30 |
CR20140279A (es) | 2014-08-04 |
JP2015500206A (ja) | 2015-01-05 |
GT201400099A (es) | 2015-03-23 |
CO6990666A2 (es) | 2014-07-10 |
IL232674A0 (en) | 2014-07-31 |
SG11201402533YA (en) | 2014-09-26 |
EP2782601A4 (en) | 2015-09-16 |
AU2012340878A1 (en) | 2014-06-12 |
WO2013078135A3 (en) | 2014-09-04 |
BR112014012121A2 (pt) | 2019-09-24 |
MX2014006160A (es) | 2014-10-24 |
KR20140097430A (ko) | 2014-08-06 |
RU2014125220A (ru) | 2015-12-27 |
EP2782601A2 (en) | 2014-10-01 |
IN2014CN04582A (zh) | 2015-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL271804A (en) | Mice producing binding proteins containing VL domains | |
IL270223B (en) | Molecules that specifically bind tdp–43 | |
LTPA2019012I1 (lt) | Plazmos kalikreiną surišantys baltymai | |
HK1202444A1 (zh) | 結合蛋白 | |
IL222980A0 (en) | Il-1 binding proteins | |
HK1198630A1 (zh) | 蛋白質載體連接的前藥 | |
EP2681239B8 (en) | Antigen binding proteins | |
ZA201304905B (en) | TNF-a BINDING PROTEINS | |
ZA201300975B (en) | Binding proteins for hepcidin | |
IL219202A0 (en) | Il-1 binding proteins | |
IL214341A0 (en) | Il-1 binding proteins | |
ZA201205624B (en) | Cd127 binding proteins | |
DK2721152T3 (da) | Dimere bindingsproteiner baseret på modificerede ubiquitiner | |
IL235134A0 (en) | il–6 binding molecules | |
IL226157A0 (en) | Antigen binding proteins | |
EP2793918A4 (en) | HDC-SIGN LINK PEPTIDES | |
EP2793021A4 (en) | PROTEINADSORBENS | |
GB201418608D0 (en) | Peridinin-chlorophyll binding proteins | |
EP2726868A4 (en) | CELL BINDING TEST | |
GB201103961D0 (en) | Binding polypeptides | |
AU2012905651A0 (en) | GABA Binding Protein | |
GB201110613D0 (en) | Comb binding | |
HUP1100282A2 (en) | Protein factor | |
GB201113890D0 (en) | Binding surfaces | |
GB201215901D0 (en) | Protein modification |